For complete list of publications, please visit Dr. Hansen’s PubMed or GoogleScholar webpages.
Literature Reviews
(2018) Microglia in Alzheimer’s disease. Hansen DV, Hanson JE, Sheng M. Journal of Cell Biology217:459-472.
(2017) TREM2, Microglia, and Neurodegenerative Diseases. Yeh FL, Hansen DV, Sheng M. Trends in Molecular Medicine23:512-533.
(2011) Development and Evolution of the Human Neocortex. Lui JH, Hansen DV, Kriegstein AR. Cell146:18-36.
(2011) Deriving Excitatory Neurons of the Neocortex from Pluripotent Stem Cells. Hansen DV, Rubenstein JL, Kriegstein AR. Neuron 70:645-660.
Book Chapters
(2022) Microglial Blockade of the Amyloid Cascade: A New Therapeutic Frontier. Hansen DV, Cullimore BK, Johanson JC, Cheng W. Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities, The Royal Society of Chemistry,Chapter 8 (pp. 193-254).
Research Papers
(2021) TREM2 restrains the enhancement of tau pathology and neurodegeneration by β-amyloid pathology. Lee S-H, Meilandt WJ, Xie L, Gandham VD, Barck KH, Ngu H, Rezzonico M, Imperio J, Lalehzadeh G, Huntley MH, Stark KL, Foreman O, Carano RAD, Sheng M, Easton A, Friedman BA, Bohlen CJ, Hansen DV. Neuron109:1283-1301.
(2020) Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation (2020). Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van der Brug MP, Foreman O, Paw JS, Modrusan Z, Beach TG, Serrano GE, Hansen DV. Cell Reports31:107843.
(2020) Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42:Aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer’s mouse model. Meilandt WJ, Ngu H, Gogineni A, Lee S-H, Lalehzadeh G, Srinivasan K, Imperio J, Wu T, Weber M, Kruse AJ, Stark KL, Chan P, Kwong M, Modrusan Z, Friedman BA, Elstrott J, Foreman O, Easton A, Sheng M, Hansen DV. Journal of Neuroscience40:1956-1974.
(2018) Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models. Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV. Cell Reports22:832-847.
(2016) Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses. Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, Borneo J, Poon C, Ho T, Cai F, Steiner P, van der Brug MP, Modrusan Z, Kaminker J, Hansen DV. Nature Communications7:11295.
(2013) Non-epithelial stem cells and cortical interneuron production in the human ganglionic eminences. Hansen DV, Lui JH, Flandin P, Yoshikawa K, Rubenstein JL, Alvarez-Buylla A, Kriegstein AR. Nature Neuroscience16:1576-87.
(2010) Neurogenic radial glia in the outer subventricular zone of human neocortex. Hansen DV, Lui JH, Parker PR, Kriegstein AR. Nature454:554-561.
(2007) Control of Emi2 activity and stability through Mos-mediated recruitment of PP2A. Wu JQ, Hansen DV, Guo Y, Wang MZ, Tang W, Freel CD, Tung JJ, Jackson PK, Kornbluth S. Proc. Natl. Acad. Sci. USA104:16564-16569.
(2006) CaMKII and Polo-like kinase 1 sequentially phosphorylate the cytostatic factor Emi2/XErp1 to trigger its destruction and meiotic exit. Hansen DV, Tung JJ, Jackson PK. Proc. Natl. Acad. Sci. USA103:608-613.
(2004) Plk1 regulates activation of the anaphase-promoting complex by phosphorylating and triggering SCF(βTrCP)-dependent destruction of the APC inhibitor Emi1. Hansen DV, Loktev AV, Ban KH, Jackson PK. Molecular Biology of the Cell15:5623-5634.
Patents
(2019) Use of PILRA-binding agents for treatment of a disease. Tushar R Bhangale, Robert R Graham, David V Hansen, Nisha Rathore, Ali A Zarrin, Jack J Bevers III, Jianhuan Zhang. US Patent Pub. No. US 2019 / 0211098 A1.